American Association for Cancer Research
crc-22-0434_fig4.png (658.96 kB)

FIGURE 4 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma

Download (658.96 kB)
posted on 2023-07-06, 14:20 authored by Michal Nisnboym, Sarah R. Vincze, Zujian Xiong, Chaim T. Sneiderman, Rebecca A. Raphael, Bo Li, Ambika P. Jaswal, ReidAnn E. Sever, Kathryn E. Day, Joseph D. LaToche, Lesley M. Foley, Hanieh Karimi, T. Kevin Hitchens, Sameer Agnihotri, Baoli Hu, Dhivyaa Rajasundaram, Carolyn J. Anderson, Deborah T. Blumenthal, Thomas M. Pearce, Shikhar Uttam, Jessie R. Nedrow, Ashok Panigrahy, Ian F. Pollack, Frank S. Lieberman, Jan Drappatz, Itay Raphael, Wilson B. Edwards, Gary Kohanbash

Immuno-PET of 89Zr-DFO-CD69 Ab visualizes the TME after ICI treatment in a GBM mouse model. Mice were inoculated with GL261 cells, and evaluated by immuno-PET of 89Zr-DFO-CD69 Ab, comparing the treatment (ICI) group to the control group (represented by orange and blue dots, respectively). A, Schematic showing timeline of tumor inoculation, ICI treatment, tail vein injection of 89Zr-DFO-CD69 Ab, immuno-PET, and BioD. B, Representative coronal head images from immuno-PET of 89Zr-DFO-CD69 Ab of ICI-treated and control mice at designated time points. Scales show SUVs of PET (SUV; colored) and CT (HU; gray). C and D, Comparison between ICI-treated mice and control at designated time points of tumor-specific regions’ SUVmax (C) and SUVmax TBR (D). E, Representative coronal-ventral and sagittal 3D whole-body MIP PET images of 89Zr-DFO-CD69 Ab of control and ICI-treated mice acquired 6 days after tracer administration. The scale shows SUVs of PET. F, Day 6 BioD results of blood- and tumor site–associated radioactivity, assessed as %ID/g. In C, D, and F, bars show means ± SEM. Scattered dots represent individual mice. Shown are representative data of three independent experiments, n = 5 per group. C and D, Multiple unpaired t test with Welch correction. F, Two-way ANOVA with multiple comparison test (*, P < 0.05; **, P <0.01; ***, P <0.001). IP, intraperitoneal.


HHS | NIH | National Cancer Institute (NCI)

HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)



Immunotherapy may hold promise for the treatment of some patients with GBM. There is a need to assess therapy responsiveness to allow the continuation of effective treatment in responders and to avoid ineffective treatment with potential adverse effects in the nonresponders. We demonstrate that noninvasive PET/CT imaging of CD69 may allow early detection of immunotherapy responsiveness in patients with GBM.

Usage metrics

    Cancer Research Communications



    Ref. manager